WPRIM Management System> DCMS> Endocrinology and Metabolism> 2021> 36> 2

Volume: 36 Issue: 2

1. Identification of Maturity-Onset Diabetes of the Young Caused by Glucokinase Mutations Detected Using Whole-Exome Sequencing Page:468—
2. Operationalizing Treat-to-Target for Osteoporosis Page:270—278
3. Digital Therapeutics for Obesity and Eating-Related Problems Page:220—228
4. Unilateral Thyroid-Associated Orbitopathy as the Only Sign of Occult Celiac Disease: Effective Treatment with a Gluten-Free Diet Page:466—467
5. New Era for Renal-Protective Therapy in Type 2 Diabetes: Better Renal Outcomes in Patients with Type 2 Diabetes Taking Sodium-Glucose Cotransporter 2 Inhibitors versus Dipeptidyl Peptidase-4 Inhibitors Page:339—341
6. Clinical Characteristics, Management, and Potential Biomarkers of Endocrine Dysfunction Induced by Immune Checkpoint Inhibitors Page:312—321
7. In Memoriam: Remembering Professor Hun-Ki Min (1928–2021) Page:207—208
8. High Serum-Induced AhRL Is Associated with Prevalent Metabolic Syndrome and Future Impairment of Glucose Tolerance in the Elderly Page:436—446
9. Role of PCSK9 Inhibitors in Patients with Familial Hypercholesterolemia Page:279—295
10. Cardiorenal Protection in Diabetic Kidney Disease Page:256—269
11. Food Preferences and Obesity Page:209—219
12. An Update on Contraception in Polycystic Ovary Syndrome Page:296—311
13. Effect of CCL11 on In Vitro Myogenesis and Its Clinical Relevance for Sarcopenia in Older Adults Page:455—465
14. Cumulative Exposure to Metabolic Syndrome Components and the Risk of Dementia: A Nationwide Population-Based Study Page:424—435
15. Gender-Dependent Reference Range of Serum Calcitonin Levels in Healthy Korean Adults Page:365—373
16. Characteristics of Immune-Related Thyroid Adverse Events in Patients Treated with PD-1/PD-L1 Inhibitors Page:413—423
17. Efficacy and Safety of the Novel Dipeptidyl Peptidase-4 Inhibitor Gemigliptin in the Management of Type 2 Diabetes: A Meta-Analysis Page:374—387
18. Radioactive Parathyroid Adenomas on Sestamibi Scans: Low Parathyroid Hormone Secretory Potential and Large Volume Page:351—358
19. Diagnosis for Pheochromocytoma and Paraganglioma: A Joint Position Statement of the Korean Pheochromocytoma and Paraganglioma Task Force Page:322—338
20. Dopaminergic Control of the Feeding Circuit Page:229—239
21. DEHP Down-Regulates Tshr Gene Expression in Rat Thyroid Tissues and FRTL-5 Rat Thyrocytes: A Potential Mechanism of Thyroid Disruption Page:447—454
22. Diagnostic Accuracy of Computed Tomography in Predicting Primary Aldosteronism Subtype According to Age Page:401—412
23. Comparative Renal Effects of Dipeptidyl Peptidase-4 Inhibitors and Sodium-Glucose Cotransporter 2 Inhibitors on Individual Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis Page:388—400
24. Continuous Glucose Monitoring in the Hospital Page:240—255
25. Identification of Maturity-Onset Diabetes of the Young Caused by Glucokinase Mutations Detected Using Whole-Exome Sequencing Page:468—
26. Operationalizing Treat-to-Target for Osteoporosis Page:270—278
27. Digital Therapeutics for Obesity and Eating-Related Problems Page:220—228
28. Protocol for a Korean Multicenter Prospective Cohort Study of Active Surveillance or Surgery (KoMPASS) in Papillary Thyroid Microcarcinoma Page:359—364
29. Associations of GNAS Mutations with Surgical Outcomes in Patients with Growth Hormone-Secreting Pituitary Adenoma Page:342—350
30. Protocol for a Korean Multicenter Prospective Cohort Study of Active Surveillance or Surgery (KoMPASS) in Papillary Thyroid Microcarcinoma Page:359—364
31. Associations of GNAS Mutations with Surgical Outcomes in Patients with Growth Hormone-Secreting Pituitary Adenoma Page:342—350
32. Unilateral Thyroid-Associated Orbitopathy as the Only Sign of Occult Celiac Disease: Effective Treatment with a Gluten-Free Diet Page:466—467
33. New Era for Renal-Protective Therapy in Type 2 Diabetes: Better Renal Outcomes in Patients with Type 2 Diabetes Taking Sodium-Glucose Cotransporter 2 Inhibitors versus Dipeptidyl Peptidase-4 Inhibitors Page:339—341
34. Clinical Characteristics, Management, and Potential Biomarkers of Endocrine Dysfunction Induced by Immune Checkpoint Inhibitors Page:312—321
35. In Memoriam: Remembering Professor Hun-Ki Min (1928–2021) Page:207—208
36. High Serum-Induced AhRL Is Associated with Prevalent Metabolic Syndrome and Future Impairment of Glucose Tolerance in the Elderly Page:436—446
37. Role of PCSK9 Inhibitors in Patients with Familial Hypercholesterolemia Page:279—295
38. Cardiorenal Protection in Diabetic Kidney Disease Page:256—269
39. Food Preferences and Obesity Page:209—219
40. An Update on Contraception in Polycystic Ovary Syndrome Page:296—311
41. Effect of CCL11 on In Vitro Myogenesis and Its Clinical Relevance for Sarcopenia in Older Adults Page:455—465
42. Cumulative Exposure to Metabolic Syndrome Components and the Risk of Dementia: A Nationwide Population-Based Study Page:424—435
43. Gender-Dependent Reference Range of Serum Calcitonin Levels in Healthy Korean Adults Page:365—373
44. Characteristics of Immune-Related Thyroid Adverse Events in Patients Treated with PD-1/PD-L1 Inhibitors Page:413—423
45. Efficacy and Safety of the Novel Dipeptidyl Peptidase-4 Inhibitor Gemigliptin in the Management of Type 2 Diabetes: A Meta-Analysis Page:374—387
46. Radioactive Parathyroid Adenomas on Sestamibi Scans: Low Parathyroid Hormone Secretory Potential and Large Volume Page:351—358
47. Diagnosis for Pheochromocytoma and Paraganglioma: A Joint Position Statement of the Korean Pheochromocytoma and Paraganglioma Task Force Page:322—338
48. Dopaminergic Control of the Feeding Circuit Page:229—239
49. DEHP Down-Regulates Tshr Gene Expression in Rat Thyroid Tissues and FRTL-5 Rat Thyrocytes: A Potential Mechanism of Thyroid Disruption Page:447—454
50. Diagnostic Accuracy of Computed Tomography in Predicting Primary Aldosteronism Subtype According to Age Page:401—412
51. Comparative Renal Effects of Dipeptidyl Peptidase-4 Inhibitors and Sodium-Glucose Cotransporter 2 Inhibitors on Individual Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis Page:388—400
52. Continuous Glucose Monitoring in the Hospital Page:240—255

©2019 - Present World Health Organization Regional Office for the Western Pacific. All Rights Reserved.